Maxscend Microelectronics Company Limited (SHE:300782)

Sage Therapeutics Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 6, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Market Capitalization	41,672	47,947	75,268	61,009	109,008	102,697
Market Cap Growth	-21.00%	-36.30%	23.37%	-44.03%	6.14%	150.25%
Enterprise Value	42,931	49,223	74,028	59,796	105,530	101,504
Last Close Price	77.90	89.58	140.45	113.66	202.43	196.08
PE Ratio	264.53	119.32	67.06	57.05	51.06	95.73
Forward PE	67.36	42.95	45.27	39.75	44.85	80.81
PS Ratio	10.28	10.69	17.19	16.59	23.53	36.78
PB Ratio	4.10	4.70	7.68	7.02	14.28	38.72
P/TBV Ratio	4.17	4.77	7.78	7.13	14.41	39.53
P/FCF Ratio	-	-	-	-	-	120.54
P/OCF Ratio	512.81	597.24	39.74	64.75	94.81	102.14
PEG Ratio	2.17	3.71	3.75	3.98	-	-
EV/Sales Ratio	10.59	10.97	16.91	16.26	22.78	36.35
EV/EBITDA Ratio	50.30	53.46	56.82	52.09	47.10	83.67
EV/EBIT Ratio	218.09	135.68	67.82	56.80	48.12	85.74
EV/FCF Ratio	-30.50	-	-	-	-	119.14
Debt / Equity Ratio	0.26	0.25	0.01	0.00	0	-
Debt / EBITDA Ratio	3.12	2.78	0.05	0.01	0.00	-
Asset Turnover	0.31	0.36	0.43	0.41	0.80	1.11
Inventory Turnover	1.26	1.44	1.52	1.28	1.92	2.73
Quick Ratio	0.70	0.67	1.75	2.39	4.31	4.83
Current Ratio	1.78	1.69	3.71	4.98	6.62	6.57
Return on Equity (ROE)	1.57%	4.03%	12.11%	13.22%	41.50%	49.22%
Return on Assets (ROA)	0.95%	1.80%	6.67%	7.33%	23.76%	29.52%
Return on Capital (ROIC)	1.05%	2.00%	7.35%	8.06%	26.65%	34.02%
Return on Capital Employed (ROCE)	1.70%	3.20%	10.80%	12.00%	28.50%	44.10%
Earnings Yield	0.38%	0.84%	1.49%	1.75%	1.96%	1.04%
FCF Yield	-3.38%	-3.73%	-0.30%	-1.26%	-1.57%	0.83%
Dividend Yield	0.13%	0.11%	0.16%	0.15%	0.22%	0.18%
Payout Ratio	106.72%	37.84%	8.09%	21.84%	8.68%	9.32%
Buyback Yield / Dilution	0.08%	0.04%	-0.18%	-0.23%	-2.73%	-14.28%
Total Shareholder Return	0.22%	0.15%	-0.02%	-0.08%	-2.51%	-14.11%

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.